Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial

TRA 2(o)P-TIMI 50 Investigators; David A Morrow; Benjamin M Scirica; Keith A A Fox; Gail Berman; John Strony; Enrico Veltri; Marc P Bonaca; Polly Fish; Carolyn H McCabe; Eugene Braunwald

doi:10.1016/j.ahj.2009.06.027

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial

TRA 2(o)P-TIMI 50 Investigators, David A Morrow, Benjamin M Scirica, Keith A A Fox, Gail Berman, John Strony, Enrico Veltri, Marc P Bonaca, Polly Fish, Carolyn H McCabe, Eugene Braunwald

Research output: Contribution to journal › Article › peer-review

Abstract

Thrombin potently activates platelets via interaction with the protease-activated receptor 1. SCH 530348 is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin via antagonism of the protease-activated receptor 1. Because SCH 530348 does not interfere with other pathways for hemostasis, it is possible that SCH 530348 reduces thrombosis with less increase in bleeding than do other potent antiplatelet agents.

Original language	English
Pages (from-to)	335-341
Number of pages	11
Journal	American Heart Journal
Volume	158
Issue number	3
DOIs	https://doi.org/10.1016/j.ahj.2009.06.027
Publication status	Published - Sep 2009

Access to Document

10.1016/j.ahj.2009.06.027

Fingerprint

Dive into the research topics of 'Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial'. Together they form a unique fingerprint.

Cite this

TRA 2(o)P-TIMI 50 Investigators, Morrow, D. A., Scirica, B. M., Fox, K. A. A., Berman, G., Strony, J., Veltri, E., Bonaca, M. P., Fish, P., McCabe, C. H., & Braunwald, E. (2009). Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. American Heart Journal, 158(3), 335-341. https://doi.org/10.1016/j.ahj.2009.06.027

TRA 2(o)P-TIMI 50 Investigators ; Morrow, David A ; Scirica, Benjamin M ; Fox, Keith A A ; Berman, Gail ; Strony, John ; Veltri, Enrico ; Bonaca, Marc P ; Fish, Polly ; McCabe, Carolyn H ; Braunwald, Eugene. / Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease : design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. In: American Heart Journal. 2009 ; Vol. 158, No. 3. pp. 335-341.

@article{a17f6a4fe8a641d5ae85324218de8567,

title = "Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial",

abstract = "Thrombin potently activates platelets via interaction with the protease-activated receptor 1. SCH 530348 is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin via antagonism of the protease-activated receptor 1. Because SCH 530348 does not interfere with other pathways for hemostasis, it is possible that SCH 530348 reduces thrombosis with less increase in bleeding than do other potent antiplatelet agents.",

author = "{TRA 2(o)P-TIMI 50 Investigators} and Morrow, {David A} and Scirica, {Benjamin M} and Fox, {Keith A A} and Gail Berman and John Strony and Enrico Veltri and Bonaca, {Marc P} and Polly Fish and McCabe, {Carolyn H} and Eugene Braunwald",

year = "2009",

month = sep,

doi = "10.1016/j.ahj.2009.06.027",

language = "English",

volume = "158",

pages = "335--341",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Mosby-Year Book Inc.",

number = "3",

}

TRA 2(o)P-TIMI 50 Investigators, Morrow, DA, Scirica, BM, Fox, KAA, Berman, G, Strony, J, Veltri, E, Bonaca, MP, Fish, P, McCabe, CH & Braunwald, E 2009, 'Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial', American Heart Journal, vol. 158, no. 3, pp. 335-341. https://doi.org/10.1016/j.ahj.2009.06.027

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease : design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. / TRA 2(o)P-TIMI 50 Investigators; Morrow, David A; Scirica, Benjamin M; Fox, Keith A A; Berman, Gail; Strony, John; Veltri, Enrico; Bonaca, Marc P; Fish, Polly; McCabe, Carolyn H; Braunwald, Eugene.

In: American Heart Journal, Vol. 158, No. 3, 09.2009, p. 335-341.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease

T2 - design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial

AU - TRA 2(o)P-TIMI 50 Investigators

AU - Morrow, David A

AU - Scirica, Benjamin M

AU - Fox, Keith A A

AU - Berman, Gail

AU - Strony, John

AU - Veltri, Enrico

AU - Bonaca, Marc P

AU - Fish, Polly

AU - McCabe, Carolyn H

AU - Braunwald, Eugene

PY - 2009/9

Y1 - 2009/9

N2 - Thrombin potently activates platelets via interaction with the protease-activated receptor 1. SCH 530348 is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin via antagonism of the protease-activated receptor 1. Because SCH 530348 does not interfere with other pathways for hemostasis, it is possible that SCH 530348 reduces thrombosis with less increase in bleeding than do other potent antiplatelet agents.

AB - Thrombin potently activates platelets via interaction with the protease-activated receptor 1. SCH 530348 is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin via antagonism of the protease-activated receptor 1. Because SCH 530348 does not interfere with other pathways for hemostasis, it is possible that SCH 530348 reduces thrombosis with less increase in bleeding than do other potent antiplatelet agents.

UR - http://www.scopus.com/inward/record.url?scp=68949156886&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2009.06.027

DO - 10.1016/j.ahj.2009.06.027

M3 - Article

C2 - 19699854

VL - 158

SP - 335

EP - 341

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -

TRA 2(o)P-TIMI 50 Investigators, Morrow DA, Scirica BM, Fox KAA, Berman G, Strony J et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. American Heart Journal. 2009 Sep;158(3):335-341. https://doi.org/10.1016/j.ahj.2009.06.027

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial

Abstract

Access to Document

Other files and links

Fingerprint

Cite this